| 证券代码：605228 | 证券简称：神通科技 | 公告编号：2025-040 | | --- | --- | --- | | 债券代码：111016 | 债券简称：神通转债 | | 神通科技集团股份有限公司 关于 2023 年限制性股票与股票期权激励计划限制 行权期间的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司股权激励管理办法》、《上海证券交易所上市公司自律监管指 南第 2 号—业务办理》、神通科技集团股份有限公司（以下简称"公司"）《2023 年限制性股票与股票期权激励计划（草案）》及中国证券登记结算有限责任公司 上海分公司关于股票期权自主行权的相关规定，结合公司 2025 年半年度业绩预 告及 2025 年半年度报告披露计划，现对处于自主行权期的股票期权限制行权时 间公告如下： 一、公司 2023 年限制性股票与股票期权激励计划首次授予股票期权第一个 行权期为 2024 年 12 月 25 日-2025 年 11 月 30 日，目前处于自主行权阶段。 二、本次限制行权期为 2025 年 ...

神通科技集团股份有限公司（以下简称"公司"）之全资子公司烟台神通汽 车部件有限公司（以下简称"烟台神通"）于近日收到了由山东省科学技术厅、 山东省财政厅、国家税务总局山东省税务局联合颁布的《高新技术企业证书》， 证书编号为 GR202437006857，有效期为三年。 本次系烟台神通在原高新技术企业证书有效期满后进行的重新认定，根据国 家有关规定，烟台神通自本次通过高新技术企业认定起连续三年内（2024 年至 2026 年）可享受高新技术企业的相关优惠政策，即按 15%的税率缴纳企业所得 税。 特此公告。 | 证券代码：605228 | 证券简称：神通科技 | 公告编号：2025-041 | | --- | --- | --- | | 债券代码：111016 | 债券简称：神通转债 | | 神通科技集团股份有限公司 关于全资子公司获得高新技术企业证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 7 月 1 日 神通科技集团股份有限公司董事会 ...

关于 神通科技集团股份有限公司 向不特定对象发行可转换公司债券受托管理 事务报告 （2024 年度） | 债券代码 | 债券简称 | | --- | --- | | 111016 | 神通转债 | 浙商证券股份有限公司 债券受托管理人 （注册地址：浙江省杭州市五星路 201 号） 二〇二五年六月 1 重要声明 浙商证券股份有限公司（以下简称"浙商证券""受托管理人"）根据《中 华人民共和国证券法》《公司债券发行与交易管理办法》《公司债券受托管理 人执业行为准则》等法律法规、自律规则等规范性文件要求，以及受托管理的神 通科技集团股份有限公司（以下简称"神通科技""发行人"或"公司"）存续 期可转换公司债券募集说明书、受托管理协议等债券发行信息披露文件约定要 求进行编制。 浙商证券编制本报告的内容及信息均来源于发行人对外公布的《神通科技 集团股份有限公司 2024 年年度报告》及相关公开信息披露文件、第三方中介机 构出具的专业意见以及发行人向浙商证券提供的其他材料。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相 关事宜作出独立判断，而不应将本报告中的任何内容据以作为浙商证券所作的 承诺或声明。 ...

Core Viewpoint - The credit rating of Shentong Technology Group Co., Ltd. is maintained at AA- with a stable outlook, reflecting the company's solid customer relationships, manageable debt levels, and optimized leverage, despite challenges in product sales and profitability [3][10][20]. Financial Overview - Total assets for the company as of 2025 Q1 are approximately 28.33 billion, with total liabilities at 12.96 billion and total debt at 8.26 billion [9][25]. - The company's net profit for 2024 is projected to be a loss of 0.32 billion, down from a profit of 0.55 billion in 2023 [9][20]. - Operating revenue is expected to decline from 16.38 billion in 2023 to 13.89 billion in 2024 [9][20]. Business Risks - The company faces declining sales volumes and profitability due to a persistent downturn in the fuel vehicle market and uncertainties surrounding new investment projects [10][20][24]. - The automotive parts market is experiencing pressure, with a notable decrease in demand for traditional fuel vehicles, impacting the company's core business [12][15][20]. Market Position - Shentong Technology maintains stable relationships with high-quality customers, including major automotive manufacturers, which provides a degree of order stability [10][15][17]. - The company is focusing on expanding its customer base in the new energy vehicle sector, although traditional vehicle demand remains weak [15][17]. Investment Projects - The company is currently developing a new optical lens production facility, with an investment of 6.26 billion planned, which is expected to enhance product diversification [19][20]. - The project is anticipated to reach operational status by July 2026, with a production capacity of 10.3 million units annually [19][20]. Operational Efficiency - The company has implemented several automated production lines to improve efficiency, although production volumes have been affected by the downturn in fuel vehicle sales [15][16]. - The production and sales rates for key components remain high, indicating effective inventory management despite market challenges [18][24]. Research and Development - R&D expenditures account for 6.13% of operating revenue, reflecting the company's commitment to innovation and maintaining competitive advantages [19][20]. - The company holds 623 patents, including 109 invention patents, which supports its product development capabilities [19][20]. Debt Management - The company's debt levels are relatively low, with a total debt to EBITDA ratio of 1.71, indicating manageable financial leverage [25][24]. - As of March 2025, the company has unused bank credit lines totaling 3.08 billion, providing additional liquidity [24][27]. Conclusion - Overall, Shentong Technology Group Co., Ltd. is navigating a challenging market environment with a focus on maintaining customer relationships, optimizing operations, and pursuing new investment opportunities, while managing financial risks effectively [10][20][24].

Core Viewpoint - The company, Shentong Technology Group Co., Ltd., has maintained its credit ratings for both its convertible bonds and its overall entity, with both rated at "AA-" and a stable outlook [1][2][3]. Group 1: Credit Ratings - The previous rating for "Shentong Convertible Bonds" was "AA-", with a stable outlook [1]. - The current rating for "Shentong Convertible Bonds" remains "AA-", with a stable outlook [2]. - The credit rating agency responsible for the assessment is China Chengxin International Credit Rating Co., Ltd. [1][2]. Group 2: Rating Report - The tracking credit rating report was released on May 29, 2024, and is available on the Shanghai Stock Exchange website [3]. - The company's credit rating has not changed from the previous assessment [3].

| 证券代码：605228 | 证券简称：神通科技 | | --- | --- | | 债券代码：111016 | 债券简称：神通转债 | | | 公告编号：2025-039 | 神通科技集团股份有限公司 关于向不特定对象发行可转换公司债券 2025 年度跟踪评级结果的公告 公司前次主体信用等级为"AA-"，评级展望为"稳定"，"神通转债"债 券信用等级为"AA-"，评级机构为中诚信，评级时间 2024 年 5 月 29 日。 中诚信在对公司经营状况等进行综合分析与评估的基础上，于 2025 年 6 月 17 日出具了《神通科技集团股份有限公司 2025 年度跟踪评级报告》，本次公司 主体信用等级为"AA-"，评级展望为"稳定"；"神通转债"债券信用等级为"AA-"。 本次评级结果较前次没有变化。 本次跟踪评级报告详见公司同日于上海证券交易所网站（www.sse.com.cn） 披露的《神通科技集团股份有限公司 2025 年度跟踪评级报告》。 前次"神通转债"评级：AA-，主体评级：AA-，评级展望：稳定 本次"神通转债"评级：AA-，主体评级：AA-，评级展望：稳定 根据中国证券监督管理委员会《上市公司证券 ...

编号：信评委函字[2025]跟踪 0553 号 神通科技集团股份有限公司 2025 年度跟踪评级报告 声 明 中诚信国际信用评级有限责任公司 2025 年 6 月 17 日 2 神通科技集团股份有限公司 2025 年度跟踪评级报告 本次评级为委托评级，中诚信国际及其评估人员与评级委托方、评级对象不存在任何其他影响本次评级行为独立、 客观、公正的关联关系。 本次评级依据评级对象提供或已经正式对外公布的信息，以及其他根据监管规定收集的信息，中诚信国际按照相关 性、及时性、可靠性的原则对评级信息进行审慎分析，但中诚信国际对于相关信息的合法性、真实性、完整性、准 确性不作任何保证。 中诚信国际及项目人员履行了尽职调查和诚信义务，有充分理由保证本次评级遵循了真实、客观、公正的原则。 评级报告的评级结论是中诚信国际依据合理的内部信用评级标准和方法、评级程序做出的独立判断，未受评级委托 方、评级对象和其他第三方的干预和影响。 本评级报告对评级对象信用状况的任何表述和判断仅作为相关决策参考之用，并不意味着中诚信国际实质性建议任 何使用人据此报告采取投资、借贷等交易行为，也不能作为任何人购买、出售或持有相关金融产品的依据。 中 ...

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 股东持股的基本情况 神通科技集团股份有限公司（以下简称"公司"）股东宁波必恒创业投资合伙企业（有限合伙）（以下简 称"必恒投资"）持有公司无限售条件流通股64,590,323股，占公司总股本的15.04%（因公司目前处于 2023年限制性股票与股票期权激励计划首次授予股票期权第一个行权期及可转换公司债券转股期，本公 告中的"持股比例"和"计划减持比例"根据公司2025年6月5日总股本429,354,910股计算得出）。上述无限 售条件流通股于2024年1月22日解除限售并上市流通。 ● 减持计划的主要内容 股东必恒投资因自身资金需求，计划通过集中竞价及大宗交易方式减持其持有的公司股份合计不超过 12,880,640股，减持比例不超过公司总股本的3.00%。其中，拟通过集中竞价交易减持公司股份不超过 4,293,547股，即不超过公司总股本的1.00%；拟通过大宗交易减持公司股份不超过8,587,093 ...

| 证券代码：605228 | 证券简称：神通科技 公告编号：2025-038 | | --- | --- | | 债券代码：111016 | 债券简称：神通转债 | 神通科技集团股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 神通科技集团股份有限公司（以下简称"公司"）股东宁波必恒创业投资合伙 企业（有限合伙）（以下简称"必恒投资"）持有公司无限售条件流通股 64,590,323 股，占公司总股本的 15.04%（因公司目前处于 2023 年限制性股票与股票期权激 励计划首次授予股票期权第一个行权期及可转换公司债券转股期，本公告中的 "持股比例"和"计划减持比例"根据公司 2025 年 6 月 5 日总股本 429,354,910 股计算得出）。上述无限售条件流通股于 2024 年 1 月 22 日解除限售并上市流通。 减持计划的主要内容 股东必恒投资因自身资金需求，计划通过集中竞价及大宗交易方式减持其持 有的公司股份合计不超过 12,880, ...